Supraventricular Tachycardia In Patients Research Articles

Risk of death and thromboembolic events in patients with supraventricular arrhythmias admitted to the emergency department

Abstract Background Few data are available on the risk of death and thromboembolism in patients with supraventricular tachycardia (SVT). Purpose To assess the risk of adverse events in SVT patients admitted to the emergency department (ED). Methods Retrospective study utilizing a global federated health research network (TriNetX). Based on the ICD codes recorded at the ED admission, patients were categorized in: SVT (I41.1), atrial fibrillation (AF, I48.0,1,2,91), atrial flutter (I48.3,4,92), and a control group with palpitations (R00.2) without arrhythmias (CTRL). Primary outcome was the 1-year risk of a composite of all-cause death and thromboembolism (ischemic stroke, transient ischemic attack, and peripheral arterial embolism). Secondary outcomes were the 1-year risk of each component of the composite outcome. Cox-regression analysis was used to produce hazard ratios (HRs) and 95% confidence intervals (CI) after 1:1 propensity score matching (PSM). The exploratory analysis was performed to assess the risk of first episode of thromboembolism. Other sensitivity analyses were performed to validate the results of the main analysis in patients ≥65 years, with multimorbidity, and not on oral anticoagulation (OAC). Results We identified 37,793 SVT patients (58.5±19.2 years, 55.8% females), 239,490 AF patients (70±19.2 years, 47.3% females), 20,674 atrial flutter patients (68.6±15.1, 15.1% females), and 89,152 CTRL (43.5±17.8 years, 60.1% females). Before PSM, in SVT patients the mean age and the prevalence of cardiovascular risk factors was lower than AF and atrial flutter patients but higher than CTRL. After PSM, no difference was found among the three groups. After PSM, the risk of composite outcome in SVT patients was higher compared to CTRL (HR 2.80, 95%CI 2.61-3.00), similar to atrial flutter patients (HR 0.98, 95%CI 0.94-1.03), and a lower compared to AF patients (HR 0.85, 95%CI 0.82-0.88) (Figure 1). These results were consistent also for the secondary outcomes, for the risk of the first thromboembolic event (Figure 2), and in all the sensitivity analyses. Conclusion SVT patients have a risk of death and thromboembolism comparable to those with atrial flutter, but lower than AF. Further studies are needed to evaluate the possible beneficial effect of OAC in this clinical context.Figure 1Figure 2

Incidence of Fetal Arrhythmia Before and During the COVID-19 Pandemic: A Single-Center Experience.

Fetal arrhythmias are rare and carry significant morbidity and mortality without appropriate treatment. Initial reports exist of fetal arrhythmia in the setting of maternal COVID-19 infection. Our study sought to evaluate incidence of fetal arrhythmia before and during the COVID-19 pandemic at our institution. This retrospective cohort study from a tertiary care fetal cardiac center utilized the institutional REDCap database to search fetal arrhythmia diagnostic codes. Medical records of mother-fetus dyads were reviewed and data were collected on diagnoses, gestational age, treatment regimen, and postnatal outcomes. Patients were divided into pre-COVID and peri-COVID segments. 8368 total pregnancies were evaluated during the 7.3years of study period. Forty-five patients (0.5%) had a significant fetal arrhythmia and were included in this study: 19 (42%) in the pre-COVID-19 group and 26 (58%) in the peri-COVID-19 group. No patients had associated congenital heart disease. There was a notable increase in the incidence of fetal supraventricular tachycardia (SVT) (1.82 per 1000 vs 2.65 per 1000 pregnancies) and complete heart block (1.04 per 1000 vs 1.77 per 1000 pregnancies) but no apparent change in other tachyarrhythmias during the COVID era. The proportion of antibody-mediated complete heart block increased from 50 to 87.5%. There was also an increase in the percentage of SVT patients requiring postnatal treatment during COVID-19 (53.8% vs 62.5%). Our experience shows an increased incidence of some fetal arrhythmia diagnoses during the COVID-19 pandemic. Additional multi-center studies will be necessary to fully evaluate the increased burden of fetal arrhythmias during the COVID-19 era as well as to elucidate etiology.

Does Cardiac Arrhythmia Predict Worse Outcome in Mild or Moderate Covid-19 Infection?

Covid-19 is a multisystem disease with the lungs being predominantly affected. Cardiac involvement is mostly seen as a rise in troponins, arrhythmias, and ventricular dysfunction. This study aimed to estimate the incidence of arrhythmias seen in Covid-19 infection and assess if arrhythmias predict worsening or mortality. Prospective observational study involving patients with mild to moderate Covid illness admitted in a tertiary care centre. Among the 85 patients (Mean age 45.8 + 14.1years; 75.31% men), worsening of Covid-19 illness was seen in 29 (34.1%) patients. New onset arrhythmias were detected on Holter in 9 (10.5%) patients. Supraventricular tachycardia was seen in 7 (8.2%) patients of whom 6 showed worsening which was statistically significant (p-value-0.006). Risk factors associated with worsening on univariate analysis were male gender (OR [95%CI] = 6.93(1.49-32.31), p-value - 0.014), new onset supraventricular tachycardia (OR [95% CI] = 14.35 [1.64-125.94], p-value - 0.016) and D-dimer elevation (OR [95% CI] = 1.00(1.00-1.01), p-value - 0.02). On multivariate analysis D-dimer (OR [95% CI] = 1.00(1.00-1.01; p-value 0.046) and supraventricular arrhythmias (OR [95% CI] = 11.12 (1.22-101.14); p-value - 0.033) were independently associated with worsening. Covid-19 infection can lead to cardiac arrhythmias. The development of supraventricular tachycardia in patients with Covid-19 infection predicts higher morbidity and worsening.

Prognostic value of cardiac troponin in elderly patients with paroxysmal supraventricular tachycardia: A multicenter study

BackgroundAn elevated level of cardiac troponin I (cTnI) frequently accompanies an episode of supraventricular tachycardia (SVT). However, the predictive value of cTnI in elderly SVT patients has not been examined. MethodsWe collected the electronic medical records of elderly SVT patients (over 65 years old) who visited four Taiwanese emergency departments over a 2-year period. The patients who underwent cTnI testing were included in the cohort and further categorized based on their cTnI results (positive or negative). The study's primary outcomes were the 5-year risks of major adverse cardiovascular events (MACE) and SVT recurrence. ResultsOne hundred and twenty-four patients met the inclusion criteria. Of these patients, 39 (31.5%) had a positive cTnI result, and 85 (68.5%) had a negative cTnI result. Patients with a positive cTnI result were older (p = 0.029) and had a longer hospital stay (p = 0.023) than those with a negative cTnI result. Multivariate analysis showed that age > 75 years (OR = 2.41; 95% CI 1.07–5.45; p = 0.034) was an independent predictor for cTnI elevation. In the survival analysis, no difference in the incidence of five-year MACE (p = 0.656) was observed between the cTnI-positive and cTnI-negative groups. Multivariate analysis revealed that a history of coronary artery disease was the only significant independent risk factor for MACE (HR = 4.30; 95% 95% CI 1.41–13.05; p = 0.010). For SVT recurrence, the multivariate analysis revealed that previous SVT (HR = 3.37; 95% CI 1.53–7.39; p = 0.002), smoking history (HR = 2.32; 95% CI 1.03–5.24; p = 0.043), and RFA treatment (HR = 0.20; 95% CI 0.06–0.65; p = 0.008) were significant independent predictors. ConclusionsAn increased cardiac troponin level may not effectively indicate the risk of MACE in elderly SVT patients. Physicians might want to be cautious when interpreting troponin test results for this specific patient group.

Algorithms for the prevention and treatment of supraventricular tachycardia in patients with implanted pacemakers: case series

Two clinical cases of prevention and relief of supraventricular tachycardia using modern algorithms in pacemakers of the latest generation in patients with bradyarrhythmia and paroxysmal atrial fibrillation (AF) are presented. In the first clinical case, the patient did not have an episode of AF for six months. In the second clinical case, the patient for 2 years did not have an episode of AF lasting more than 1 minute. Episodes sinus rhythm restoration by antitachypacing algorithms were recorded. These clinical cases demonstrate the effectiveness of modern algorithms in pacemakers of the latest generation for the AF prevention and sinus rhythm restoration.

Comparison of sinus conversion rates and body weights after 6 mg adenosine administration in supraventricular tachycardia

BackgroundTo evaluate the relationship between body weight and the success rate of supraventricular tachycardia (SVT) termination after an initial 6-mg adenosine administration. MethodsThis retrospective observational study was conducted with medical records of patients who visited a single tertiary emergency department and underwent an electrophysiologic study with an SVT diagnosis. Patients under 18 years of age or those with SVT aberrancy, recurring SVT after radiofrequency catheter ablation, premedication of non-dihydropyridine calcium channel blocker, and signs of shock were excluded. ResultsData from 124 patients were collected. There were 69 women (55.6%); mean age, 49.7 years. The mean weight and height were 66.8 kg and 164.8 cm, respectively. Adenosine dose was 0.09 mg/kg. For the first sinus conversion (SC) success group (83 patients, 67%), the mean weight, height, and adenosine dose were 61.0 ± 11.5 kg, 161.9 ± 8.1 cm, and 0.10 ± 0.02 mg/kg. For the first SC failure group, these values were 78.4 ± 17.0 kg, 170.7 ± 8.9 cm, and 0.079 ± 0.02 mg/kg, respectively. To evaluate factors associated with the first SC, we performed bivariate logistic regression with weight (odds ratio [OR]: 1.093; 95% confidence interval [CI]: 1.045–1.144; P < 0.001) and height (OR: 1.071; 95% CI: 1.008–1.138; P = 0.027). Receiver operating characteristics curves and the cut-off values for adenosine dose and weight were 0.90 mg/kg and 66.5 kg with 71.1% sensitivity and 73.2% specificity (area under the curve: 0.814; 95% CI: 0.73–0.90; P < 0.001). ConclusionWeight and height were significant predictors of the first SC success rate among SVT patients. Consequentially, it is necessary to consider other adenosine administration methods, including increasing the initial drug dose or changing the flushing strategy after adenosine injection.

146 Clinical Outcomes of Supraventricular Tachycardia in Patients Primarily Hospitalized with Acute Kidney Injury

146 Clinical Outcomes of Supraventricular Tachycardia in Patients Primarily Hospitalized with Acute Kidney Injury

Antiarrhythmic Medication in Neonates and Infants with Supraventricular Tachycardia

Supraventricular tachycardia (SVT) is the most common arrhythmia in neonates and infants, and pharmacological therapy is recommended to prevent recurrent episodes. This retrospective study aims to describe and analyze the practice patterns, effectiveness, and outcome of drug therapy for SVT in patients within the first year of life. Among the 67 patients analyzed, 48 presented with atrioventricular re-entrant tachycardia, 18 with focal atrial, and one with atrioventricular nodal re-entrant. Fetal tachycardia was reported in 27%. Antiarrhythmic treatment consisted of beta-receptor blocking agents in 42 patients, propafenone in 20, amiodarone in 20, and digoxin in 5. Arrhythmia control was achieved with single drug therapy in 70% of the patients, 21% needed dual therapy, and 6% triple. Propafenone was discontinued in 7 infants due to widening of the QRS complex. After 12 months (6–60), 75% of surviving patients were tachycardia-free and discontinued prophylactic treatment. Patients with fetal tachycardia had a significantly higher risk of persistent tachycardia (p: 0.007). Prophylactic antiarrhythmic medication for SVT in infancy is safe and well tolerated. Arrhythmia control is often achieved with single medication, and after cessation, most patients are free of arrhythmias. Infants with SVT and a history of fetal tachycardia are more prone to suffer from persistent SVT and relapses after cessation of prophylactic antiarrhythmic medication than infants with the first episode of SVT after birth.

Dyssynchronous cardiomyopathy in patients with WPW syndrome and its reversibility after RFA of accessory pathway

Abstract Introduction In some cases accessory pathway-mediated ventricular preexcitation can be associated with electro-mechanical dyssynchrony and, consequently, with dyssynchrony-related dilated cardiomyopathy, even in the absence of supraventricular tachycardia (SVT). Sometimes rapid progression of ventricular dysfunction developed in such patients after birth. Methods and materials 8 patients with asymptomatic WPW and dyssynchronous cardiomyopathy were examined in our Institute from 2017 till 2019. Four patients of the group were observed in other clinics with dilated cardiomyopathy (DCM) and prescribed appropriate therapy without significant clinical effect. The absence of complaints of heartbeat and episodes of tachycardia at the scheduled Holter monitoring allowed eliminating incessant tachycardia as a possible cause of cardiomyopathy. After radiofrequency ablation (RFA) all patients were performed ECG to assess QRS duration, Holter monitoring, echocardiography (Echo) for assessment of heart chamber volume and left ventricle (LV) contractile function and Speckle tracking – Echo with LV longitudinal strain assessment. The average age of the patients was 9.5 years (from 2 to 14 years). 6 children had heart failure (NYHA Class II). Results According to Echo all patients had widened QRS complex. Dilatation and enlargement of LV volume were marked in 6 pts. According to Echo7 patients had decrease of LV contractile function. According to Speckle tracking – Echo all patients had intraventricular dyssynchrony, decrease of longitudinal strain indices. At intracardiac electrophysiology study right-sided accessory pathways was diagnosed in all patients, successful RFA was performed. Preexitation relapsed, and the repeated RFA was performed in 2 pts. Complications caused by RFA were not marked. After RFA all patients showed a regular normalization of QRS duration. At the 5th day after RFA Echo was performed to all patients. The patients with initially decreased LV ejection fraction had it increased. The patients with initial dilatation and LV volume enlargement had normalization of the given indices. According to Speckle tracking – Echo normalization of global and regional myocardial function, LV longitudinal strain, disappearance of intraventricular and interventricular dyssynchrony were marked in all patients. The index of longitudinal strain was 17,0±0,64% before RFA, after RFA - 23,75±0,92% (p=0,ehab724.035946). Conclusion As a result of RFA of accessory pathways electromechanical resynchronization causes LV demodeling and restoration of its contractile ability. The presented clinical examples are an additional indication for RFA of accessory pathways even in the absence of SVT in patients regardless of age. Funding Acknowledgement Type of funding sources: None.

The Effectiveness of Adenosine in Treating the Acute Attacks of Supra-ventricular Tachycardia

Background: Adenosine is a natural adenine nucleoside available endogenously that decreases heart beat by blocking atrioventricular (AV) node transiently so that extend the duration of conduction in (AV) node when injected intravenously. It has a curative value in the conversion of majority of supraventricular tachycardia (SVT) to sinus rhythm. In order to evaluate the adenosine in the management of arrhythmias we conduct this study. Objective: This study was conducted to evaluate the safety and efficacy of intravenous adenosine therapy for treatment of (SVT), to determine the optimal adenosine dose effective in (SVT), and to determine the underlying conditions affecting the effective dose. And to evaluate the effectiveness of vagal maneuvers in terminating of spontaneous SVT patients and methods: A cross-sectional study conducts in a group consist of 69 patients ranged from 23-70 years old admitted to the Coronary care unit in Azadi Teaching Hospital ,in Kirkuk city, from July 2014 to June 2016. The diagnosis of (SVT) was made by present of tachycardia which is of narrow complex with a heart beat rate greater than 140 beats/ min by 12 leads chest electrocardiography (ECG). In patients who are hemodynamically stable, vagal maneuvers were carried out initially in the form of carotid sinus massage, gag reflex and Valsalva maneuver, if this failed intravenous administration of adenosine as recommended doses were preformed. If three doses of adenosine boluses were unsuccessful to convert the arrhythmia, patients were managed with other available antiarrythmias or managed with direct electrical cardio version (DC). In unstable patients were managed with (DC). Results: Of 69 included patients, diagnosed as (SVT), M: F ratio was 1:2.1. Their age ranged from 23 years to 70 years with mean age of 57 years. Vagal maneuvers (VM) resulted in restoration of sinus rhythm (SR) in 8patients (7.6%). Out of 57 episodes of (SVT), Adenosine was effective in reverting 51 episodes of SVT to sinus rhythm (89.5%). Of those converted, 18 required a single dose (6mg) (31.6%), fifteen required one additional (12mg) dose (26.3%), and another 18 required two additional doses (81mg) (31.6%).four patients were hemo-dynamically unstable (systolic blood pressure <90 mm Hg) which required (DC). Six patients (10.5%) not responding to full adenosine dose(81mg), started treatment with other medication, 1 with verapamil, 4 with amiodarone, and1 with digoxin. All of them were successfully treated. Conclusions: Adenosine is an effective medicine in treating (SVT) in those patients in whom vagal maneuvers has unsuccessful. It demonstrates a high rate of success in terminating acute attack of SVT. A higher dose may be required in majority of patients specially

A new score model to predict the inducibility of supraventricular tachycardia in patients with palpitation without documented electrocardiography.

Although electrophysiological study (EPS) is one of the most useful diagnostic approaches to detect the cardiac origin of palpitations, there is no clear indication for EPS in patients with palpitation in the absence of documented supraventricular tachycardia (SVT). In this study, we aimed to create a new SVT score model to detect the requirement of EPS in patients with palpitation without documented tachycardia. A total of 154 patients with palpitation were included in this study. To create the SVT score, we considered four main criteria with their subunits. They were severity, frequency, duration, and termination of the symptoms. EPS was performed on all the patients after their scoring assessment. Median SVT score of induced tachycardia and non-induced patients was determined as 10 and 6 points, respectively; and it was found to be statistically significant; p<0.001. The cut-off value for inducibility was found to be 7.5 points through receiver operating characteristic curve analysis, (94.9% sensitivity, 92.1% specificity), and the area under the curve was determined to be 97.2 (94.8-99.5, p<0.001). According to our new SVT score model, ≥8 points strongly correlates with the inducibility of SVT during EPS.

Long term prognosis in patients with pulmonary hypertension undergoing catheter ablation for supraventricular tachycardia

Various forms of supraventricular tachycardia (SVT) occur in patients with severe pulmonary hypertension (PH). Despite the high efficacy of radiofrequency catheter ablation (RFCA) for SVT, insufficient data exist regarding patients with PH. Thirty SVTs in 23 PH patients (age 47 [35–60] years; mean pulmonary artery pressure 44 [32–50] mmHg) were analyzed. Procedural success rate, short- and long-term clinical outcomes, were evaluated during a median follow-up of 5.1 years. Single-procedure success rate was 83%; 94% (17/18) in typical atrial flutter, 73% (8/11) in atrial tachycardia (AT), and 100% (1/1) in atrioventricular nodal reentrant tachycardia. Antiarrhythmic drugs, serum brain natriuretic peptide levels and number of hospitalizations significantly decreased after RFCA than that before (p = 0.002, 0.04, and 0.002, respectively). Four patients had several procedures. After last RFCA, 12 patients had SVT and 8 patients died. Kaplan–Meier curves showed that patients with SVT after the last RFCA had a lower survival rate compared to those without (p = 0.0297). Multivariate analysis identified any SVT after the last RFCA as significant risk factor of mortality (hazard ratio: 9.31; p = 0.016). RFCA for SVT in patients with PH is feasible and effective in the short-term, but SVT is common during long-term follow-up and associated with lower survival.

Radiofrequency Catheter Ablation of Supraventricular Tachycardia in Patients With Pulmonary Hypertension: Feasibility and Long-Term Outcome.

BackgroundSupraventricular tachycardia (SVT) occurs commonly and is strongly correlated with clinical deterioration in patients with pulmonary hypertension (PH). This study aimed to investigate the feasibility and long-term outcome of radiofrequency catheter ablation (RFCA) in PH patients with SVT.Materials and MethodsConsecutive PH patients with SVT who were scheduled to undergo electrophysiological study and RFCA between September 2010 and July 2019 were included. The acute results and long-term success of RFCA were assessed after the procedure.ResultsIn total, 71 PH patients with 76 episodes of SVT were analyzed. Cavotricuspid isthmus-dependent atrial flutter (n = 33, 43.5%) was the most common SVT type, followed by atrioventricular nodal reentrant tachycardia (n = 16, 21.1%). Of the 71 patients, 60 (84.5%) underwent successful electrophysiological study and were subsequently treated by RFCA. Among them, acute sinus rhythm was restored in 54 (90.0%) patients, and procedure-related complications were observed in 4 (6.7%) patients. Univariate logistic regression analysis showed that cavotricuspid isthmus-independent atrial flutter [odds ratio (OR) 25.00, 95% confidence interval (CI) 3.45–180.98, p = 0.001] and wider pulmonary artery diameter (OR 1.19, 95% CI 1.03–1.38; p = 0.016) were associated with RFCA failure. During a median follow-up of 36 (range, 3–108) months, 7 patients with atrial flutter experienced recurrence, yielding a 78.3% 3-year success rate for RFCA treatment.ConclusionThe findings suggest that RFCA of SVT in PH patients is feasible and has a good long-term success rate. Cavotricuspid isthmus-independent atrial flutter and a wider PAD could increase the risk for ablation failure.

Catheter ablation of supraventricular tachycardia in patients with and without structural heart disease: insights from the German ablation registry

AimTo compare patient characteristics, safety and efficacy of catheter ablation of supraventricular tachycardia (SVT) in patients with and without structural heart disease (SHD) enrolled in the German ablation registry.Methods and resultsFrom January 2007 until January 2010, a total of 12,536 patients (37.2% with known SHD) were enrolled and followed for at least one year. Patients with SHD more often underwent ablation for atrial flutter (45.8% vs. 20.9%, p < 0.001), whereas patients without SHD more often underwent ablation for atrioventricular nodal reentrant tachycardia (30.2% vs. 11.8%, p < 0.001) or atrioventricular reentrant tachycardia (9.1% vs. 1.6%, p < 0.001). Atrial fibrillation catheter ablation procedures were performed in a similar proportion of patients with and without SHD (38.1% vs. 36.9%, p = 0.21).Overall, periprocedural success rate was high in both groups. Death, myocardial infarction or stroke occurred in 0.2% and 0.1% of patients with and without SHD (p = 0.066). Major non-fatal complications prior to discharge were rare and did not differ significantly between patients with and without SHD (0.5% vs. 0.4%, p = 0.34). Kaplan–Meier mortality estimate at 1 year demonstrated a significant mortality increase in patients with SHD (2.6% versus 0.7%; p < 0.001).ConclusionPatients with and without SHD undergoing SVT ablation exhibit similar success rates and low major complication rates, despite disadvantageous baseline characteristics in SHD patients. These data highlight the safety and efficacy of SVT ablation in patients with and without SHD. Nevertheless Kaplan–Meier mortality estimates at 1 year demonstrate a significant mortality increase in patients with SHD, highlighting the importance of treating the underlying condition and reliable anticoagulation if indicated.

The prevalence and clinical outcome of supraventricular tachycardia in different etiologies of pulmonary hypertension.

PurposePatients with pulmonary hypertension (PH) frequently suffer from supraventricular tachycardias (SVT). The main purpose of our study was to identify the cumulative incidence of SVT in patients with different etiologies of PH. The secondary objective was to analyse the clinical impact of SVT.MethodsWe retrospectively studied the prevalence of SVT and the clinical outcome in 755 patients (41% males; 60 ± 15 years; mean follow-up 3.8 ± 2.8 years) with PH of different etiologies. The prevalence of SVT was analysed separately in isolated pre-capillary PH (Ipc-PH) and in patients with combined post- and pre-capillary PH (Cpc-PH).ResultsThe prevalence of SVT in the Ipc-PH group (n = 641) was 25% (n = 162). The most prevalent arrhythmias were atrial fibrillation followed by a typical atrial flutter (17% and 4.4% of all Icp-PH patients). An excessive prevalence of SVT was found in patients with pulmonary arterial hypertension associated with congenital heart disease (35%, p = 0.01). Out of the overall study population, Cpc-PH was present in 114 (15%) patients. Patients with Cpc-PH manifested a higher prevalence of SVT than subjects with Ipc-PH (58; 51% vs. 162; 25%; p <0.0001) and were more likely to have persistent or permanent atrial fibrillation (38; 29% vs. 61; 10%; p <0.0001). Parameters significantly associated with mortality in a multivariate analysis included age, male gender, functional exercise capacity and right atrial diameter (p < 0.05). Neither diagnosis of SVT nor type of arrhythmia predicted mortality.ConclusionsThe study detected a significant prevalence of SVT in the population of PH of different origins. Different spectrum and prevalence of arrhythmia might be expected in different etiologies of PH. Patients with an elevated post-capillary pressure showed a higher arrhythmia prevalence, predominantly due to an excessive number of atrial fibrillations. The diagnosis of SVT was not associated with mortality.

Supraventricular tachycardia in patients with coronary sinus stenosis/atresia: Prevalence, anatomical features, and ablation outcomes.

Supraventricular tachycardia (SVT) with coronary sinus (CS) ostial atresia (CSA) or coronary sinus stenosis (CSS) causes difficulty in electrophysiological procedures, but its characteristics are poorly understood. Study the anatomical and clinical features of SVT patients with CSA/CSS. Of 6128 patients with SVT undergoing electrophysiological procedures, consecutive patients with CSA/CSS were enrolled, and the baseline characteristics, imaging materials, intraoperative data, and follow-up outcomes were analyzed. Thirteen patients, seven with CSA and sixwith CSS, underwent the electrophysiological procedure. Decapolar catheters were placed into the proximal CS in three cases, while the rest were placed at the free wall of the right atrium. Fourteen arrhythmias were confirmed: four atrioventricular nodal reentrant tachycardias, five left-sided accessory pathways, three paroxysmal atrial fibrillations, and two atrial flutters (AFLs). In addition to three patients who underwent only an electrophysiological study, the acute ablation success rate was 100% in 10 cases, with no procedure-related complications. After a median follow-up period of 59.6 months, only one case of atypical AFL recurred. For those cases (seven CSA and two CSS) with a total of 10 anomalous types of CS drainage, three types were classified: from the CS to the persistent left superior vena cava (n = 3), from an unroofed CS (n = 3), and from the CS to the small cardiac vein (n = 3) or Thebesian vein (n = 1). Patients with CSA/CSS may develop different kinds of SVT. Electrophysiological procedures for such patients are feasible and effective. An individualized mapping strategy based on the three types of CS drainage will be helpful.

Paediatric supraventricular tachycardia patients potentially more at risk of developing psychological difficulties compared to healthy peers.

Assess executive and socio-emotional/behavioural functioning in paediatric supraventricular tachycardia (SVT) patients. SVT patients aged 7-17 who had not undergone catheter ablation were included. Parents completed the Child Behaviour Checklist (CBCL/6-18) and the Behavior Rating Inventory of Executive Functioning (BRIEF). Participants age 11-17years completed the Youth Self-Report (YSR/11-18) and the BRIEF Self-Report (BRIEF-SR). One-sample z test was used to compare questionnaire results to the average t-score range (M=50, SD=10). Thirty (18 female) children/adolescents participated (M=12.6years old, SD=3.2years) with a mean SVT onset age of 7years (SD=4.3years). BRIEF and BRIEF-SR results suggested no difference in executive functioning from average. Mean t-scores of CBCL/6-18 and YSR/11-18 subscales Anxious/Depressed, Withdrawn/Depressed, Somatic Complaints, Thought Problems, Diagnostic and Statistical Manual of Mental Disorders (DSM) Affective Problems, DSM Anxiety Problems and DSM Somatic Problems were significantly elevated compared to average. YSR/11-18 subscales Social Problems, Attention Problems, Internalizing Problems, DSM ADHD Problems and DSM Oppositional Defiant Problems had elevated mean t-scores compared to average. Effect sizes were small to medium (0.2≤d≤0.8). Paediatric patients with SVT potentially have a greater risk of developing behaviour, especially internalizing, problems compared to similarly aged children/adolescents without SVT.

Effects of Red and Blue Light on the Cardiac Autonomic Nervous System

Purpose: Light is an important environmental stimulus influencing everyday life. However, information about the impact of coloured light on the autonomic nervous system (ANS) is sparse. In general, red light (RL) is thought to act as an adrenergic trigger, while there is evidence that blue light (BL) induces parasympathetic activation. This is a pilot study to find out, if RL and/or BL affects heart rate variability (HRV). Methods: Participants were randomly exposed first to neutral light (NL) and then to RL and BL for 120 minutes in a special light cabin. During each test run, HRV measurements were performed using both wrist training computers and Holter-ECGs. Furthermore, heart rate, arrhythmias and blood pressure were analysed. All parameters were measured during neutral and repeated during RL or BL in 10 supraventricular tachycardia patients, in 10 patients with heart failure and 10 athletes. Results: During exposure to both RL and BL an increase of blood pressure, improvements of several HRV parameters, but no significant change of heart rate was observed. Neither RL nor BL influenced the occurrence of ectopic beats in Holter ECGs. The most prominent improvement of HRV was found in athletes, whereas increase in blood pressure were comparable between all three groups. Conclusion: RL and BL influence the cardiac ANS. Since no differences were found between different light scenarios, the changes can not solely be attributed to the two-sided model of sympathetic and parasympathetic effects of ANS. However, RL and BL could potentially be used therapeutically to influence HRV in athletes.

Paroxysmal supraventricular tachycardia in patient with dilated cardiomyopathy and concomitant cardiac conduction defects: a case report and discussion

Patients with dilated cardiomyopathy (DCM) often have intraventricular conduction disorders, which contribute to aggravation of heart failure, are progressive in most cases and can specify the prognosis of the disease. Paroxysmal supraventricular arrhythmias in such patients proceed with severe clinical manifestations, often accompanied by hemodynamic instability and syncope. A case report of patient (59 years old) with DCM, reduced left ventricular ejection fraction (35-37%), left bundle branch block, and paroxysmal orthodromic reciprocating tachycardia is presented. When an electrode was inserted on the right ventricular (RV) apex during the radiofrequency ablation, a third-degree atrioventricular (AV) block was recorded. This was maintained during the operation and was recurrent when trying to remove the electrode from the RV apex, and therefore there was a need for temporary and then permanent cardiac pacing therapy. Given DCM, reduced left ventricular ejection fraction, left bundle branch block, and the expected high percentage of RV pacing, a decision was made to implant a cardiac resynchronization therapy defibrillator. The literature review considers risk factors for formation of third-degree AV block during cardiac catheterization, methods of its prevention, as well as discusses the prognostic significance of catheter-induced conduction disorders, and indications for temporary and permanent cardiac pacing therapy.

P921Feasibility of multipoint, high-definition mapping with grid cathether of SVTs in patients with D-Transposition of the great arteries treated with atrial switch surgery

Abstract Introduction Patients with D-transposition of the great arteries (TGA) treated with Senning or Mustard surgery develop supraventricular tachycardias (SVTs) that require treatment with ablation. The use of multipoint, high-density, wavefront-activation-orientation independent mapping catheters hasn’t been reported in literature. Purpose To describe the feasibility of using a specific mapping catheter in SVTs in this set of patients. Methods Prospective observational study in patients with history of SVT and atrial switch surgery, that underwent EP study and electroanatomic (EA) mapping with a new 8Fr deflectable, multipoint (16 equidistant electrodes along 4 splines), with magnetic sensor, wavefront-activation-orientation independent catheter, in a third level hospital since April 2018 until May 2019, with medium-term follow-up. Results A total of 8 EPS (electrophysiologic studies) were performed in 7 patients (clinical data in Table 1). One patient had a tachycardia recurrence, accounting for a second EPS. The pulmonary venous atrium (PVA) was mapped in all procedures, whereas the systemic venous atrium (SVA) was mapped only in 75% of them, A total of 15 EA maps were obtained, with a ratio of 1.9 maps/patient, and an average of 20 375 ± 13 045 total points per patient. In all cases, PVA mapping was performed via retrograde transaortic approach, without transbaffle puncture. Tachycardia was induced in 5 out of 8 procedures, obtaining 6 different tachycardias (4 CTI dependent macro-reentry: 3 w/anticlockwise activation; 1 localized re-entry in SVA; 1 focal AT in SVA). No arrhythmia was induced in the other 3 procedures, however, in a patient with a previous CTI ablation, evidence of a gap in the ablation line on the voltage map was found. Ablation was performed with an irrigated, contact force, 3.5 mm catheter in 6 of the 8 procedures (75%). A retrograde transaortic approach was used in 3 of CTI dependent macro-reentries (75%). In one patient (who underwent two procedures) ablation was performed through a baffle leak. We report an acute success rate of ablation of 100%, and a recurrence rate of 20% on medium-term follow up. There were no major complications; nonetheless, one patient with history of morbid obesity had a minor vascular complication on the femoral puncture site treated medically. Conclusions it’s feasible and safe to use this new mapping catheter in patients with history of atrial switch surgery, both via retrograde and anterograde approach on the PVA and SVA respectively. The most frequent tachycardia observed in this study was anticlockwise CTI-dependent atrial flutter. Abstract Figure. Patient characteristics